Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study

OBJECTIVE: The Systemic Lupus Erythematosus (SLE) Responder Index (SRI), developed as a primary outcome measure for use in clinical trials, captures improvement in SLE disease activity without concomitant worsening in disease manifestations. This study investigated the relationships between the SRI...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vollenhoven, Ronald F, Stohl, William, Furie, Richard A, Fox, Norma Lynn, Groark, James G, Bass, Damon, Kurtinecz, Milena, Pobiner, Bonnie F, Eastman, William J, Gonzalez‑Rivera, Tania, Gordon, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical Trials and Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280901/
https://www.ncbi.nlm.nih.gov/pubmed/30588323
http://dx.doi.org/10.1136/lupus-2018-000288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280901/
https://www.ncbi.nlm.nih.gov/pubmed/30588323
http://dx.doi.org/10.1136/lupus-2018-000288

Ejemplares similares